PMID- 25560580 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20200106 IS - 2299-5684 (Electronic) IS - 1734-1140 (Linking) VI - 67 IP - 1 DP - 2015 Feb TI - The MCP-1, CCL-5 and SDF-1 chemokines as pro-inflammatory markers in generalized anxiety disorder and personality disorders. PG - 85-9 LID - S1734-1140(14)00267-9 [pii] LID - 10.1016/j.pharep.2014.08.006 [doi] AB - INTRODUCTION: The co-occurrence of generalized anxiety disorder and personality disorders suggests the existence of association between the neurobiological predispositions leading to the development of these disorders and activation of cytokine system. Pro-inflammatory chemokines such as CCL-5/RANTES (regulated upon activation normal T cell expressed and secreted) and CXCL12/SDF-1 (stromal derived factor) play an important role in immune response. METHODS: A total of 160 participants were enrolled in the study, 120 of whom comprised the study group (people with the dual diagnosis of personality disorder and generalized anxiety disorder). The mean age was 41.4 +/- 3.5 years (range: 20-44 years). The control group consisted of 40 healthy individuals in the mean age of 40.8 +/- 3.1 years (range: 20-43 years). A blood sample was collected from each participant and the plasma levels of the CCL-2/MCP-1 (monocyte chemoattractant protein-1), RANTES and SDF-1 chemokines were determined by ELISA. RESULTS: Increased levels of MCP-1 and SDF-1 were found both in women and in men versus the control group for all types of personality disorders. The levels of CCL-5 in men were significantly increased versus the control group and significantly higher in women than in men. Neither women nor men with avoidant or obsessive-compulsive personality disorder showed any significant differences in MCP-1 or SFD-1 levels. In subjects with borderline personality disorder, the levels of the study chemokines were higher in women than in men. CONCLUSIONS: Our study has shown the need for determination of proinflammatory interleukins which are considered as biomarkers of personality disorders and generalized anxiety disorders. CI - Copyright (c) 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved. FAU - Oglodek, Ewa A AU - Oglodek EA AD - Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland. Electronic address: maxeva@interia.pl. FAU - Szota, Anna M AU - Szota AM AD - Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland. FAU - Just, Marek J AU - Just MJ AD - Piekary Medical Centre, Department of General Surgery, Municipal Hospital in Piekary Slaskie, Piekary Slaskie, Poland. FAU - Mos, Danuta M AU - Mos DM AD - Health Care Centre Euro-Med Bytom, Bytom, Poland. FAU - Araszkiewicz, Aleksander AU - Araszkiewicz A AD - Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland. LA - eng PT - Journal Article DEP - 20140821 PL - Switzerland TA - Pharmacol Rep JT - Pharmacological reports : PR JID - 101234999 RN - 0 (Biomarkers) RN - 0 (CCL2 protein, human) RN - 0 (CCL5 protein, human) RN - 0 (CXCL12 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (Chemokine CCL5) RN - 0 (Chemokine CXCL12) SB - IM MH - Adult MH - Anxiety Disorders/*blood/psychology MH - Biomarkers/*blood MH - Chemokine CCL2/*blood MH - Chemokine CCL5/*blood MH - Chemokine CXCL12/*blood MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Male MH - Obsessive-Compulsive Disorder/blood/psychology MH - Personality Disorders/*blood/psychology MH - Sex Characteristics MH - Young Adult OTO - NOTNLM OT - Chemokine OT - Generalized anxiety disorder OT - Personality disorders EDAT- 2015/01/07 06:00 MHDA- 2016/04/19 06:00 CRDT- 2015/01/07 06:00 PHST- 2014/05/25 00:00 [received] PHST- 2014/08/06 00:00 [revised] PHST- 2014/08/08 00:00 [accepted] PHST- 2015/01/07 06:00 [entrez] PHST- 2015/01/07 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] AID - S1734-1140(14)00267-9 [pii] AID - 10.1016/j.pharep.2014.08.006 [doi] PST - ppublish SO - Pharmacol Rep. 2015 Feb;67(1):85-9. doi: 10.1016/j.pharep.2014.08.006. Epub 2014 Aug 21.